Understanding how EYA3 and PP2A contribute to the spread of triple negative breast cancer
Deciphering the role of EYA3/PP2A in triple negative breast cancer metastasis
This study is looking at how a protein called EYA3, which is found in high amounts in triple negative breast cancer, works with another protein, PP2A, to see how they affect cancer spread and the immune system, with the hope of finding new treatment options for this tough-to-treat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11121618 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which EYA3, a protein that is overexpressed in triple negative breast cancer (TNBC), interacts with another protein, PP2A, to influence the metastasis of this aggressive cancer type. The study aims to uncover how these proteins affect the immune response and tumor growth, particularly focusing on the tumor microenvironment that can either promote or inhibit immune cell activity. By analyzing these interactions, the research seeks to identify potential new therapeutic targets for TNBC, which currently has limited treatment options due to its unique characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple negative breast cancer who are seeking new treatment options.
Not a fit: Patients with non-triple negative breast cancer subtypes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that specifically target the mechanisms of metastasis in triple negative breast cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting similar molecular pathways in other cancer types, suggesting that this approach may yield beneficial results for TNBC as well.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Ford, Heide L. — University of Colorado Denver
- Study coordinator: Ford, Heide L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.